Simplified calculation of month-on-month annualized peritoneal dialysis associated peritonitis rate – Validation in ANZDATA, NZ PD and RDPLF registries
Simplified Calculation of Monthly PD Peritonitis Rate
Keywords:RDPLF, ANZDATA, Peritoneal dialysis, NZ PD Registry, Peritonitis
Peritonitis is the most important therapy-related complication of peritoneal dialysis (PD). Monthly or quarterly PD peritonitis rate statistics are used to identify special cause variation within or between individual PD centres, to highlight any need for quality improvement. Unfortunately, many PD centres do not accurately “patient flow” (i.e., when patients start and finish on PD), and therefore cannot measure PD peritonitis rate. In this study, we validate an estimating formula for month-on-month annualised PD peritonitis rate, that calculates time-at-risk from “patient stock” (i.e., the number of prevalent patients on PD at the beginning and end of the month). We compared centers’ estimated peritonitis rates with gold-standard measurements in the Australia and New Zealand Dialysis and Transplant Registry / New Zealand PD Registry, and Le Registre de Dialyse Péritonéale de Langue Française et hémodialyse à domicile. A total of 268 centers from 9 countries with 1,020,260 patient-months of follow-up and 19,669 episodes of peritonitis were modeled. Overall agreement was excellent between estimates and gold-standard measurements with a concordance correlation coefficient (CCC) of 0.998 (95% confidence interval [CI] 0.998-0.998) in both registries. There was statistically significant lower agreement for smaller centers, although the CCC was still greater than 0.995. There were no instances of clinically significant misclassification of centers as being compliant or non-compliant with PD peritonitis standards with the use of the estimating formula. The simplified method of calculating the PD peritonitis rate is accurate and will allow more centers around the world to measure, report, and work on reducing PD peritonitis rates.
2. Marshall MR, Waters G, Verger C. Peritoneal Dialysis Associated Peritonitis Rate - Validation of a Simplified Formula. Bull Dial Domic 2021;4(4).
3. Hayat A, Collins J, Saweirs W. Study of early complications associated with peritoneal dialysis catheters: an analysis of the New Zealand Peritoneal Dialysis Registry data. Int Urol Nephrol. 2021;53(8):1705-11.
4. Hayat A, Saweirs W. Predictors of technique failure and mortality on peritoneal dialysis: An analysis of New Zealand peritoneal dialysis registry data. Nephrology (Carlton). 2021;26(6):530-40.
5. McDonald SP, Russ GR, Kerr PG, Collins JF. ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. Am J Kidney Dis. 2002;40(6):1122-31.
6. Verger C, Fabre E, Veniez G, Padernoz MC. Synthetic 2018 data report of the French Language Peritoneal Dialysis and Home Hemodialysis Registry (RDPLF). Bull Dial Domic. 2019;2(1):1-7 DOI:10.25796/bdd.v2i1.19093.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases. 1987;40(5):373-83.
8. Lin LI-K. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45(1):255-68.
9. Lin LI-K. Assay Validation Using the Concordance Correlation Coefficient. Biometrics. 1992;48(2):599-604.
10. Lin LI-K. A note on the concordance correlation coefficient. Biometrics. 2000;56(1):324-5.
11. Krippendorff K. Bivariate Agreement Coefficients for Reliability of Data. Sociological Methodology. 1970;2:139-50.
12. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-10.
13. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219.
14. Marshall MR. A systematic review of peritoneal dialysis-related peritonitis rates over time from national or regional population-based registries and databases. Peritoneal Dialysis International. 2021;42(1):39-47.
How to Cite
Copyright (c) 2022 Mark Marshall
This work is licensed under a Creative Commons Attribution 4.0 International License.